$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix

$cpix Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000162828018014380 Filed on November 14, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	$10.49M	$5.853M	$11.65M
YoY Change	-9.97%	-47.72%	28.28%
Cost Of Revenue	$1.510M	$1.460M	$2.150M
YoY Change	-29.77%	-32.58%	33.54%
Gross Profit	$600.0K	$4.393M	$9.500M
YoY Change	-93.68%	-51.35%	27.01%
Gross Profit Margin	5.72%	75.05%	81.55%
Selling, General & Admin	$2.870M	$6.871M	$8.790M
YoY Change	-67.35%	-17.39%	31.0%
% of Gross Profit	478.33%	156.41%	92.53%
Research & Development	$2.940M	$1.306M	$980.0K
YoY Change	200.0%	38.48%	-15.52%
% of Gross Profit	490.0%	29.73%	10.32%
Depreciation & Amortization	$870.0K	$720.0K	$680.0K
YoY Change	27.94%	9.09%	11.48%
% of Gross Profit	145.0%	16.39%	7.16%
Operating Expenses	$6.640M	$8.177M	$10.40M
YoY Change	-36.15%	-11.7%	23.37%
Operating Profit	-$3.293M	-$2.645M	-$903.3K
YoY Change	264.57%	215.08%	-5.65%
Interest Expense	$30.00K	$19.20K	$60.00K
YoY Change	-50.0%	115.67%	200.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.020M	-$1.660M	-$840.0K
YoY Change	616.67%	120.31%	-10.64%
Income Tax	$0.00	$4.159K	$80.00K
% Of Pretax Income
Net Earnings	-$2.220M	-$1.643M	-$800.5K
YoY Change	177.32%	121.13%	6.78%
Net Earnings / Revenue	-21.17%	-28.07%	-6.87%
Basic Earnings Per Share	-$0.14	-$0.11	-$0.05
Diluted Earnings Per Share	-$0.14	-$0.11	-$0.05
COMMON SHARES
Basic Shares Outstanding	15.53M shares	15.57M shares	15.75M shares
Diluted Shares Outstanding		15.57M shares

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.23M	$47.79M	$50.09M
YoY Change	-27.66%	-4.56%	-0.09%
Cash & Equivalents	$27.94M	$38.26M	$45.41M
Short-Term Investments	$8.291M	$9.534M	$4.672M
Other Short-Term Assets	$2.964M	$2.352M	$3.467M
YoY Change	-14.5%	-20.17%	27.87%
Inventory	$9.783M	$6.426M	$6.738M
Prepaid Expenses
Receivables	$6.460M	$7.055M	$8.395M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$59.12M	$63.63M	$68.68M
YoY Change	-13.93%	-3.72%	4.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$771.2K	$539.0K	$528.9K
YoY Change	45.82%	13.54%	13.87%
Goodwill	$784.0K		$0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.531M	$2.809M	$2.487M
YoY Change	1.79%	24.68%	17.26%
Total Long-Term Assets	$53.58M	$23.81M	$24.55M
YoY Change	118.26%	-1.91%	-11.89%
TOTAL ASSETS
Total Short-Term Assets	$59.12M	$63.63M	$68.68M
Total Long-Term Assets	$53.58M	$23.81M	$24.55M
Total Assets	$112.7M	$87.43M	$93.23M
YoY Change	20.87%	-3.23%	-0.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.211M	$8.447M	$8.980M
YoY Change	-8.57%	6.64%	11.74%
Accrued Expenses	$16.04M		$8.715M
YoY Change	84.11%		29.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.80M	$15.52M	$17.69M
YoY Change	57.13%	-1.77%	19.62%
LONG-TERM LIABILITIES
Long-Term Debt	$20.00M	$12.00M	$9.800M
YoY Change	104.08%	50.0%	139.02%
Other Long-Term Liabilities	$9.319M	$2.000M	$1.816M
YoY Change	413.18%	25.0%	30.51%
Total Long-Term Liabilities	$9.319M	$14.00M	$1.816M
YoY Change	413.18%	45.83%	30.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.80M	$15.52M	$17.69M
Total Long-Term Liabilities	$9.319M	$14.00M	$1.816M
Total Liabilities	$57.12M	$29.49M	$29.31M
YoY Change	94.89%	15.94%	44.5%
SHAREHOLDERS EQUITY
Retained Earnings	$4.746M	$6.966M	$11.71M
YoY Change	-59.47%	-44.31%	-37.06%
Common Stock	$51.10M	$51.24M	$52.41M
YoY Change	-2.5%	-2.57%	-4.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$55.84M	$58.20M	$64.12M
YoY Change
Total Liabilities & Shareholders Equity	$112.7M	$87.43M	$93.23M
YoY Change	20.87%	-3.23%	-0.18%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	-$2.220M	-$1.643M	-$800.5K
YoY Change	177.32%	121.13%	6.78%
Depreciation, Depletion And Amortization	$870.0K	$720.0K	$680.0K
YoY Change	27.94%	9.09%	11.48%
Cash From Operating Activities	$3.720M	-$1.640M	-$460.0K
YoY Change	-908.7%	-265.66%	-156.1%
INVESTING ACTIVITIES
Capital Expenditures	-$2.700M	-$860.0K	-$480.0K
YoY Change	462.5%	681.82%	0.0%
Acquisitions
YoY Change
Other Investing Activities	-$18.72M	$5.280M	$3.380M
YoY Change	-653.85%	-16.72%	-434.65%
Cash From Investing Activities	-$21.41M	$4.430M	$2.910M
YoY Change	-835.74%	-28.66%	-294.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.370M	-430.0K	940.0K
YoY Change	684.04%	-315.0%	-361.11%
NET CHANGE
Cash From Operating Activities	3.720M	-1.640M	-460.0K
Cash From Investing Activities	-21.41M	4.430M	2.910M
Cash From Financing Activities	7.370M	-430.0K	940.0K
Net Change In Cash	-10.32M	2.360M	3.390M
YoY Change	-404.42%	-68.11%	-425.96%
FREE CASH FLOW
Cash From Operating Activities	$3.720M	-$1.640M	-$460.0K
Capital Expenditures	-$2.700M	-$860.0K	-$480.0K
Free Cash Flow	$6.420M	-$780.0K	$20.00K
YoY Change	32000.0%	-170.91%	-98.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001087294
CY2018Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2017Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15555865	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15723075	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15555865	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15723075	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	Cumberland Pharmaceuticals Inc.
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15527623	shares
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38259233	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45412868	USD
CY2018Q3	us-gaap	Marketable Securities MarketableSecurities	9533703	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	4672476	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7055138	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8395112	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	6426429	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	6737848	USD
CY2018Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2351708	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3466541	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	63626211	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	68684845	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539019	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	528882	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20370330	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21444545	USD
CY2018Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	87210	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	87210	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2809306	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2486830	USD
CY2018Q3	us-gaap	Assets Assets	87432076	USD
CY2017Q4	us-gaap	Assets Assets	93232312	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	8447429	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8979929	USD
CY2018Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7070860	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8714814	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	15518289	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17694743	USD
CY2018Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	12000000	USD
CY2017Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	9800000	USD
CY2018Q3	cpix	Other Long Term Obligations Excluding Current Portion OtherLongTermObligationsExcludingCurrentPortion	1969174	USD
CY2017Q4	cpix	Other Long Term Obligations Excluding Current Portion OtherLongTermObligationsExcludingCurrentPortion	1815968	USD
CY2018Q3	us-gaap	Liabilities Liabilities	29487463	USD
CY2017Q4	us-gaap	Liabilities Liabilities	29310711	USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	51235612	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	52410941	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	6966252	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	11709222	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	58201864	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	64120163	USD
CY2018Q3	us-gaap	Minority Interest MinorityInterest	-257251	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	-198562	USD
CY2018Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57944613	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63921601	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87432076	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93232312	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8492530	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11196961	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27243859	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29500843	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1460463	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2166353	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4511743	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5216776	USD
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4803112	USD
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6226438	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14549873	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	16174391	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1306055	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	943162	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4631384	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2921951	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2067981	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2090785	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6732485	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6554158	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	661802	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	609572	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1946457	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1811589	USD
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	10299413	USD
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	12036310	USD
	us-gaap	Costs And Expenses CostsAndExpenses	32371942	USD
	us-gaap	Costs And Expenses CostsAndExpenses	32678865	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1806883	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-839349	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5128083	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3178022	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	166220	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	94833	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	398420	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	216849	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	19199	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	8902	USD
	us-gaap	Interest Expense InterestExpense	59520	USD
	us-gaap	Interest Expense InterestExpense	70646	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1659862	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-753418	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4789183	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3031819	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4159	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3822	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12477	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4196192	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-1664021	USD
CY2017Q3	us-gaap	Profit Loss ProfitLoss	-757240	USD
	us-gaap	Profit Loss ProfitLoss	-4801660	USD
	us-gaap	Profit Loss ProfitLoss	-7228011	USD
CY2018Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-20977	USD
CY2017Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14209	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-58689	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-49923	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-1643044	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-743031	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4742971	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7178088	USD
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15573108	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15867159	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15645230	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15973737	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15573108	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15867159	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15645230	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15973737	shares
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1643044	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-743031	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4742971	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-7178088	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	20977	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	14209	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	58689	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	49923	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1664021	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-757240	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4801660	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7228011	USD
	us-gaap	Profit Loss ProfitLoss	-4801660	USD
	us-gaap	Profit Loss ProfitLoss	-7228011	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2108051	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1974194	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4293963	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1005239	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	849198	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	91109	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	44117	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	60708	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	131652	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	48084	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1339974	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-124748	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-311419	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	485739	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-966817	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	428176	USD
	cpix	Increase Decrease In Current Operating Liabilities IncreaseDecreaseInCurrentOperatingLiabilities	-1595243	USD
	cpix	Increase Decrease In Current Operating Liabilities IncreaseDecreaseInCurrentOperatingLiabilities	640453	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	142486	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	239703	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-610452	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98152	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	171731	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	172899	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20851951	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2029414	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	16122376	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9644592	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1411710	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	841647	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6313016	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6600632	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	36000000	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	14700000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	33800000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	10800000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	200909	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	248108	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2382968	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2893857	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-230167	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1006143	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7153635	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7508623	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45412868	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34510330	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38259233	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42018953	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63921601	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	200909	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1005239	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2381477	USD
	us-gaap	Profit Loss ProfitLoss	-4801660	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2018Q3	us-gaap	Trading Securities TradingSecurities	9533703	USD
CY2017Q4	us-gaap	Trading Securities TradingSecurities	4672476	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-1643044	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-743031	USD
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15573108	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15867159	shares
CY2018Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15573108	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15867159	shares
	us-gaap	Net Income Loss NetIncomeLoss	-4742971	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7178088	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15645230	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15973737	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15645230	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15973737	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18325	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14175	shares
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8492530	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11196961	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27243859	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29500843	USD
CY2018Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	100000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2018Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2510870	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3156002	USD
CY2018Q3	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	423987	USD
CY2017Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	249964	USD
CY2018Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3491572	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3331882	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	6426429	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	6737848	USD
CY2010Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000	USD
CY2016Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000	USD
CY2017Q4	cpix	Stock Issued During Period Shelf Registration Proceeds From Saleof Corporate Securities StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities	100000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	200000	USD
CY2018Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	12000000.0	USD
CY2017Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	9800000	USD
CY2018Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	100000	USD

Files In Submission

Name	View Source	Status
0001628280-18-014380-index-headers.html	Edgar Link	pending
0001628280-18-014380-index.html	Edgar Link	pending
0001628280-18-014380.txt	Edgar Link	pending
0001628280-18-014380-xbrl.zip	Edgar Link	pending
cpix-20180930.htm	Edgar Link	pending
cpix-20180930.xsd	Edgar Link	pending
cpix-20180930_cal.xml	Edgar Link	unprocessable
cpix-20180930_def.xml	Edgar Link	unprocessable
cpix-20180930_htm.xml	Edgar Link	completed
cpix-20180930_lab.xml	Edgar Link	unprocessable
cpix-20180930_pre.xml	Edgar Link	unprocessable
cpixq32018-exhibit101.htm	Edgar Link	pending
cpixq32018-exhibit311.htm	Edgar Link	pending
cpixq32018-exhibit312.htm	Edgar Link	pending
cpixq32018-exhibit321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix

2018 Q4 Form 10-Q Financial Statement

#000162828018014380 Filed on November 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPIX CUMBERLAND PHARMACEUTICALS INC Stock $cpix

2018 Q4 Form 10-Q Financial Statement

#000162828018014380 Filed on November 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix